Sonoma Pharmaceuticals, Inc. has published its quarterly earnings report for the period ending September 30, 2026. This report is significant for the company as it outlines its financial performance and operational developments during the second quarter of the fiscal year.

Sonoma Pharmaceuticals is a company that specializes in the development and marketing of surgical and medical instruments and apparatus. It operates under the ticker SNOA on the Nasdaq exchange. The company is classified under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. Recent filings include a 10-Q on November 10, 2026, and an S-3 on November 13, 2026.

The latest filing states, "The conformed submission type is 10-Q, and the report covers the period from April 1, 2026, to September 30, 2026." This report provides a snapshot of the company's financial health, including revenue, net income, and other key metrics that are essential for stakeholders.

The impact of this filing may affect various stakeholders, including investors, analysts, and competitors within the surgical and medical instruments sector. As companies in this industry strive to innovate and improve their offerings, Sonoma's performance will likely be a point of reference for others in the market.

Looking ahead, the filing does not specify what happens next for Sonoma Pharmaceuticals. However, the company is expected to continue focusing on its growth strategies and operational efficiencies in the coming quarters.